Celyad Reports Half Year 2019 Financial Results and Second Quarter Business Highlights

Celyad Reports Half Year 2019 Financial Results and Second Quarter Business Highlights

Celyad to Provide First Half 2019 Financial Results & Business Highlights and Host a Conference Call

Celyad to Provide First Half 2019 Financial Results & Business Highlights and Host a Conference Call

Celyad Presents Update on Autologous & Allogeneic NKG2D-based CAR-T Therapies in Solid Tumors

Celyad Presents Update on Autologous & Allogeneic NKG2D-based CAR-T Therapies in Solid Tumors

Celyad to Host Conference Call to Review Clinical Update from ESMO 21st World GI Congress

Celyad to Host Conference Call to Review Clinical Update from ESMO 21st World GI Congress

Celyad Announces Strategic Updates to the Autologous r/r AML and MDS Program

Celyad Announces Strategic Updates to the Autologous r/r AML and MDS Program

Celyad Presents Clinical Update for CYAD-01 at 24th Congress of the European Hematology Association

Celyad Presents Clinical Update for CYAD-01 at 24th Congress of the European Hematology Association

Celyad to Participate in Upcoming June 2019 Conferences

Celyad to Participate in Upcoming June 2019 Conferences

Celyad to Present Data at 24th Congress of the European Hematology Association

Celyad to Present Data at 24th Congress of the European Hematology Association

Celyad Announces First Quarter 2019 Financial Results and Recent Business Highlights

Celyad Announces First Quarter 2019 Financial Results and Recent Business Highlights

Celyad Announces May 2019 Investor Conference Schedule

Celyad Announces May 2019 Investor Conference Schedule

Celyad to Present Update on allogeneic and autologous NKG2D-based CAR-T Candidates in Refractory mCRC at ESMO 21st World GI Congress

Celyad to Present Update on allogeneic and autologous NKG2D-based CAR-T Candidates in Refractory mCRC at ESMO 21st World GI Congress

Celyad Announces April 2019 Investor Conference Schedule

Celyad Announces April 2019 Investor Conference Schedule